Solid Tumor Clinical Trial
Official title:
Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor
This study was designed as a single-center, open, non-randomized trial.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | July 1, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Age 18-70 years old, regardless of gender. 2. Condition body mass index (BMI) = Weight (kg)/Height 2 (m2), the body mass index is in the range of 18-28 (Including the cut-off value). 3. Patients with locally advanced or metastatic solid tumors that have been clearly diagnosed by histology/cytology, patients whose condition is stable after standard treatment, or those who have failed standard treatment. 4. According to the Eastern Cooperative Oncology Group (ECOG) score of 0 to 2, the estimated survival time is = 3 months. 5. It has sufficient organ and bone marrow functions, defined as follows: 1. Blood routine: white blood cell count (WBC) = 4.0 × 109/L; neutrophil count (NEUT) = 1.5 × 109/L; platelet count (PLT) = 100 × 109/L; hemoglobin concentration = 9.0 g/ dL; 2. Liver function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 times the upper limit of normal (ULN); for patients with liver cancer or liver metastases, ALT and AST = 5 times ULN; Total bilirubin (TBIL) = 1.5 × ULN; 3. Renal function: blood creatinine (CREA) = 1.5 × ULN; 4. Heart function: LVEF = 50%. 6. Those who have used chemotherapeutics in the past need to stop the drug for more than 4 weeks (mitomycin or nitrosourea, need to stop for more than 6 weeks); have received surgery, molecular targeted therapy, and anti-tumor indications with Chinese medicine Those who need treatment should end at least 4 weeks, and those who have received palliative radiotherapy need more than 4 weeks of treatment. 7. Any toxicity associated with previous anti-tumor treatments must have been restored to = Grade 1 (except for hair loss). 8. During the study period and within 3 months after the end of the administration, subjects with fertility (whether male or female) must receive effective contraceptive measures. 9. With my consent and signed an informed consent form by myself or my legal representative. Exclusion Criteria: 1. Suffer from any clinically significant cardiovascular and cerebrovascular diseases within 3 months before taking the trial drug, including but not limited to myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, congestive heart failure, Cerebrovascular accident (including transient ischemic attack). 2. There is NCI-CTCAE grade = grade 2 arrhythmia, any grade of atrial fibrillation that is not controlled, or the ECG found at the time of screening that the QT interval (QTc) for two consecutive corrections> 480ms. 3. Any drug that may prolong the QTc interval or induce torsade de pointes ventricular tachycardia is required within 14 days before the first use of the test drug or during treatment. 4. History of allergic diseases and severe drug allergy. 5. Patients with uncontrolled tumor brain metastases with clinical symptoms. 6. Patients with severe infections (including but not limited to progressive or active infections) (for example, intravenous infusion of antibiotics, antifungal or antiviral drugs, etc.). 7. Patients with severe medical diseases, such as cardiac dysfunction of grade II and above (NYHA standard), ischemic heart disease (such as myocardial infarction or angina), congestive heart failure and other cardiovascular diseases, poorly controlled diabetes (Fasting blood glucose =10mmol/L), poorly controlled hypertension (systolic blood pressure>150mmHg and/or diastolic blood pressure>100mmHg). 8. Those who have bleeding tendency or are receiving thrombolysis or anticoagulation therapy. 9. Active hepatitis (hepatitis B, hepatitis C) or known HIV infection. 10. Other systemic anti-tumor treatments may be accepted during the study period. 11. A clear history of neurological or mental disorders, including epilepsy or dementia. 12. Have bad habits such as drug and alcohol abuse. Alcoholism refers to drinking behaviors of 4 or more times within about 2 hours. One-time drinking refers to drinking 150ml of wine, 350ml of beer, or 50ml of 80% liquor (or equivalent to the alcohol content). 13. Women during pregnancy or lactation. 14. Those who have received other drug clinical research within 1 month before the study. 15. Other situations where the researcher thinks it is inappropriate to participate in this research. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital, China Medical University | Shenyang | Liaoning |
Lead Sponsor | Collaborator |
---|---|
Beijing Nuokangda Pharmaceutical Technology Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax | Obtain directly according to the measured data of blood drug concentration-time. | ±1 minute | |
Primary | AUC 0-t | The area under the curve from the time of administration to the lowest detectable blood concentration: calculated by the linear trapezoidal rule. | ±1 minute | |
Primary | AUC 0-8 | Area under the curve from administration to extrapolation to infinity: AUC0-8=AUC0-t+Ct/?z, Ct is the last measurable concentration, and ?z is the elimination rate constant. | ±1 minute |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |